



LUNG

LUNG DISEASE SITE COMMITTEE

AGENDA OPEN SESSION

Chelsea Hotel, Toronto, ON
Room: Churchill A
Saturday April 28, 2018, 1:30 – 4:00 pm EST

Chairs: G. Goss / Y. Ung
CCTG Senior Investigator: Dr. F. Vera-Badillo

CME Credits:

Credits for Specialists: This event is an Accredited Group Learning Activity (Section 1) as defined by the Maintenance of Certification program of the Royal College of Physicians and Surgeons of Canada, and approved by Queen's University.

CME Learning Objectives:

- To summarize recent developments in the understanding of molecular biology and therapeutics as these relate to the management of lung cancer
- To cite and analyze recent results of lung cancer clinical studies conducted by or in collaboration with the Canadian Cancer Trials Group

1:30 – 1:35 pm	Welcome and Introduction	G. Goss/Y. Ung
1:35 – 1:40 pm	Applications for Lung Radiation Working Group Chair	G. Goss/Y. Ung
1:40 – 1:45 pm	IASLC World Lung Conference on Lung Cancer (in Toronto)	N. Leigh/A. Bezjak
1:45 – 2:15 pm	<u>Report from Trial Study Chairs: Update on Current Trials:</u>	
1:45 – 1:55	<u>BR.31:</u> A Phase III Prospective Double Blind Placebo Controlled Randomized Study of Adjuvant MEDI4736 in Completely Resected Non-Small Cell Lung Cancer	G. Goss
1:55 – 2:05	<u>BRC.6 (LungMAP – S1400):</u> A Biomarker-Driven Master Protocol for Previously Treated Squamous Cell Lung Cancer	N. Leigh
2:05 – 2:15	<u>BR.34:</u> A Randomized Trial of Durvalumab (MEDI4736) and Tremelimumab +/- Platinum-Based Chemotherapy in Patients with Metastatic (Stage IV) Squamous or Non-Squamous Non-Small Cell Lung Cancer (NSCLC)	N. Leigh/S. Kulkarni



2:15 – 2:30 pm **Coffee Break**

IND Studies

2:30 – 2:40 pm **IND.226:** **R. Juergens/D. Hao**
 A Phase IB Study of Durvalumab (MEDI4736) With or Without
 Tremelimumab in Patients With Advanced Incurable Solid Malignancies
 Given With or Without Standard Chemotherapy Regimens

2:40 – 3:00 pm **IND.227:** **Q. Chu**
 A Phase II Randomized Study of Pembrolizumab in Patients With
 Advanced Malignant Pleural Mesothelioma

Reports from Committees

3:00 - 3:05 pm **IND Committee** **R. Juergens**

3:05 – 3:10 pm **Lung CSTB Committee** **M. Tsao**

3:10 - 3:15 pm **Lung Radiation/SCLC JOINT Subcommittee** **Y. Ung/B. Melosky**

3:15 – 3:20 pm **Mesothelioma/Thymoma Subcommittee** **C. Lee**

New Concepts and Proposals

3:20 – 4:00 pm **Proposed trials:** **G. Goss**

Frail Study: **T. Hsu**
 Phase III Trial of Avelumab +/- Single Agent Chemotherapy in Frail Patients
 with Metastatic Non-Small Cell Lung Cancer (NSCLC)

BR.32: **G. Goss**
 A phase II randomized trial of maintenance therapy with Talazoparib in
 combination with Avelumab versus observation in extensive disease
 small-cell lung cancer (SCLC)

CRI concept – John Hopkins collaboration **G. Goss**

Others **G. Goss**

4.00 pm **Summary and Close** **G. Goss/Y. Ung**